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Summary
In an endeavor to further characterize human intercellular adhesion molecule-2 (ICAM-2), two
murine monoclonal antibodies (mAb) were generated to ICAM-2 transfected COS cells, and
designated CBR-IC2/1 and CBR-IC2/2. Immunoprecipitated, reduced ICAM-2 migrated as
a broad band of M, 60,000 in sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Treat-
ment with N-glycanase revealed a peptide backbone of MI 31,000, consistent with the size
predicted from the cDNA. ICAM-2 had a broad distribution on hematopoietic cell lines and
little expression on other cell lines, the sole exception being cultured endothelial cells which
possess high levels of ICAM-2. Resting lymphocytes and monocytes expressed ICAM-2, while
neutrophils did not. Staining of tissue sections with anti-ICAM-2 mAb confirmed their strong
reactivityto vascular endothelium, but demonstrated a lack ofICAM-2 expression on other tissues.
Small clusters of ICAM-2 positive cells were, however, seen in germinal centers. In contrast to
ICAM-1 there was little or no induction of ICAM-2 expression on lymphocytes or cultured
endothelium upon stimulation with inflammatory mediators. One ofthe two mAb, CBRIC2/2,
was found to totally inhibit binding of ICAM-2 * COS cells to purified lymphocyte
function-associated antigen-1 (LFA-1). Using this mAb, LFA-1-dependent binding to both
stimulated and unstimulated endothelium was found to be totally accounted for by ICAM-1
and ICAM-2. Homotypic aggregation of an Epstein-Barr virus-transformed B cell line, JY, was
found to be solely ICAM-1 and ICAM-2-dependent, while in the case of the T cell lymphoma
cell line, SKW3, anti- ICAM-2 mAb in conjunction with anti-ICAM-1 mAb could not inhibit
the LFA-1-dependent aggregation. This suggests an additional LFA-1 ligand exists. Using a cell
binding assay to purified LFA-1 in conjunction with anti-ICAM-1 and anti-ICAM-2 mAb, we
have demonstrated that this putative third ligand for LFA1 exists on SKW3 and other cell lines.
A
dhesion molecules play a central role in the functions of
the immune system. These molecules direct cell-cell in-
teractions critical for antigen presentation, lymphocyte acti-
vation, localization, migration, and effector/target functions
at the site of inflammation (reviewed in reference 1). The inte-
grin family of adhesion receptors are involved in the cell-cell
and cell-matrix interactions of a wide variety of cell types
(1-4). A subgroup of the integrins, consisting of lympho-
cyte function-associated antigen-1 (LFA-1),1 Mac-1, and
p150,95 (the "leukocyte integrins") play a major role in leu-
kocyte adhesion (5). They share a common 0subunit (CD18)
noncovalently associatedwith homologous cr subunits (LFA1
t Abbreviations used in this paper. AP, alkaline phosphatase; FDC, follicular
dendritic cells; HUVEC, human umbilical vein endothelial cells; ICAM,
intercellular adhesion molecule; LFA, lymphocyte function-associated
antigen.
ci, CD11a; Mac1 u, CD11b; p150,95 ci, CD11c) (6) . Their
importance in leukocyte adhesion is most aptly demonstrated
by a clinical condition, known as leukocyte adhesion deficiency
(7). Patients have recurrent life-threatening bacterial infec-
tions due to mutations in the commona subunit, resulting
in lack of expression of all three leukocyte integrins (8).
Of the three leukocyte integrins, LFA1 has the best charac-
terized role in cell adhesion. It was first defined by the ability
of mAb to block both T cell-mediated killing and prolifera-
tion, and is required for numerous other functions including
T helper and B lymphocyte responses, natural killing, Ab-
dependent cellular cytotoxicity by monocytes and granulocytes,
and adherence of leukocytes to endothelial cells, fibroblasts,
and epithelial cells (5, 9). An inducible molecule, intercel-
lular adhesion molecule-1 (ICAM-1) (CD54), was the first
ligand discovered for LFA-1 (10, 11) . A member of the im-
munoglobulin superfamily (12, 13), ICAM-1 has five Ig-like
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residues in the first N-terminal domain (14). Most LFA1-de-
pendent phenomena couldbe inhibited by blocking mAb to
ICAM-1 (10, 15, 16). However, binding of lymphocytes to
cultured human umbilical vein endothelial cells (HUVEC)
showed that the ICAM-1 blocking mAb, RRl/1, could not
inhibit all the LFA1-dependent adhesion (15). This implied
a second ligand for LFA-1 existed on endothelial cells. Simi-
larly, LFA-1 mAb but not ICAM-1 mAb blocked PMA-
induced aggregation of a T cell lymphoblastoid cell line,
SKW3 (10). Lastly, LFAI-dependent cytolysis ofcertain target
cells by T cells was not inhibitable with mAb to ICAM-1
(16), further evidence for additional LFA-1 ligands. A cDNA
clone for a second LFA-1 ligand, termed ICAM-2, was ob-
tained by transfecting COS cells with an endothelial cDNA
library and selecting for binding to LFA-1 coated plates in
the presence ofblocking ICAM-1 mAb (17). Like ICAM-1,
ICAM-2 is a member of the immunoglobulin superfamily.
It has only two immunoglobulin-like domains that are most
homologous to the two N-terminal domains ofICAM-1, with
35% amino acid identity (17).
In this study we report on the biochemical and cellular
nature of ICAM-2 using mAb generated to COS cells tran-
siently expressing the ICAM-2 cDNA. Two murine mAb
to ICAM-2, CBR-IC2/1 and CBRIC2/2, were generated.
Using these antibodies, the cellular and tissue distribution,
biochemical properties and functional role in cell-cell adhe-
sion of ICAM-2 could be studied. ICAM-2 was found to
differ from ICAM-1 in both its distribution and inducibility,
implying a functional difference between the two molecules.
Several LFA-1-dependent, ICAM-1-independent cell inter-
actions could be accounted for by ICAM-2, whereas others
revealed the presence of a third, as yet undefined, ligand for
LFA-1.
Materials and Methods
Monoclonal Antibodies.
￿
The following previously described mu-
rine mAbs to human antigens were used: TS2/9 (anti-LFA-3, IgGl)
(18), TS2/16 (anti-CD29, IgGl) (18), TSl/22 (anti-CDlla, IgGl)
(18), RR1/1 (anti-ICAM-1, IgGl) (10), W6/32 (anti-HLAA,B,C,
IgG2a) (19), and X63 (nonbinding antibody, IgGl).
Cell Culture.
￿
The murine myeloma P3X63Ag8.653 (20) was
maintained in DMEMsupplemented with 10% FetalBovine Serum
(FBS), 5 mM glutamine and 50 kg/ml gentamyein (supplemented
DMEM) at 37°C in a humidified 10% COZ atmosphere. Hybrid-
omas were initially grown in supplemented DMEM under HAT
selection (100 FM hypoxanthine, 400 nM aminopterin, 16 /AM
thymidine), transferred to supplemented DMEM under HT selec-
tion (100/AM hypoxanthine and 16 AM thymidine) and later grown
solely in supplemented 10% FBS/DMEM. The human fibrosar-
coma cell line, FS 1,2,3 and epitheloid carcinoma cell line, HeLa,
were grown in 10% FBS/DMEM plus supplements at 37°C and
10% C02. All other human cell lines were grown in RPMI 1640
medium supplemented with 10% FBS, 5 mM glutamine and 50
Fcg/ml gentamycin at 37°C and 5% C02. All cell lines used in
this study are listed in Table 2.
Human umbilical vein endothelial cells (HUVEC, passage
number 2-4) were maintained as a monolayer on fibronectin-coated
dishes in M199 medium, 20% PBS (Hyclone Laboratories, Inc.,
Logan, UT; LPS = 0.025 ng/ml), 5 mM glutamine, 50 14g/ml
gentamycin, 100 Pg/ml endothelial growth supplement (Biomed-
ical Technologies, Inc., Stoughton, MA) and 100 jig/ml heparin
at 37°C and 5% CO2. For stimulation, 5 U/ml of recombinant
human IIr1s (Boehringer Mannheim, Indianapolis, IN), 10,ag/ml
of LPS (Sigma Chemical Co., St. Louis, MO), 20 ng/ml ofrecom-
binant human TNF-a (Genzyme, Boston, MA) or 103 U/ml of
recombinant IFN-y (Genzyme) was added to the medium at ei-
ther 4 or 24 h before harvesting. Stimulation of HUVEC was moni-
tored by flow cytometry analysis of ICAM-1 on treated and un-
treated cells.
Peripheral blood mononuclear cells (PBMC) were obtained by
dextran sedimentation and Ficoll-Hypaque (1.077) centrifugation
as described (15). Granulocytes were recovered from the cell pellet;
contaminating erythrocytes were removed by hypotonic lysis. Lym-
phocytes were enriched by incubating the PBMC in 10%
FBS/RPMI 1640 on tissue culture-treated plastic Petri dishes for
2 h and saving the nonadherent cells. To enrich for T lymphocytes,
the nonadherent cells were passed through nylon wool (21) . NK
cells were further isolated from plastic and nylon wool nonadherent
mononuclear cells by Percoll (Pharmacia Fine Chemicals, Piscataway,
NJ) gradient centrifugation as described (22). CD3' cells were re-
moved by labelling with CD3 mAb (OKT3) and removing the
mAb bound cells by rosetting with magnetic beads (Dynal; Bob-
bins Scientific, Mountain View, CA) coated with F(ab')2 goat
anti-mouse IgG and IgM (Tago Inc., Burlingame, CA). Immuno-
fluorescence flow cytometry showed the purified NK cells to be
>75% CD16' with few (<10%) contaminating CD3' cells. PHA
blasts were prepared from isolated PBMC, incubated in supple-
mented RPMI, plus 10% FBS and 10 Fig/ml PHA-P (Sigma Chem-
ical Co.) and assayed at the indicated times (23). Plastic adherent
monocytes were either analyzed immediately or cultured in vitro
for 10 d to induce differentiation towards macrophage-like cells
(24). The adherent cells were removed with HBSS/EDTA and sur-
face antigen expression examined by immunofluorescence flow
cytometry.
cDNA and Transfection.
￿
ICAM-1 and ICAM-2 cDNAs in the
transient expression vector CDM8 (13, 17) or vector alone (mock)
were transfected into COS cells using DEAE-dextran (25). 3 d after
transfection, cells were detached with 10 mM HBSS/EDTA, washed
three times in 10%FBS/RPMI 1640 and then used for immuniza-
tion, flow cytometric analysis, "5I-labeling, or binding to LFA-
1-coated plates. Cellswere washed twice with PBS, pH 7.3, before
either immunization or ...I-labeling.
Development ofICAM-2 Hybridomas.
￿
Transfected COS cells ex-
pressing ICAM-2 were used to immunize 3-12-wk-old BALB/c
female mice (Charles River Laboratories, Wilmington, MA). Im-
munizations (105-106 cells/i.p. immunization) were performed four
times at 3-wk intervals. 3 d before fusion with the murine my-
eloma P3X63Ag8.653, the mice were injected both i.p. and i.v.
with 5 x 105 COS cells transiently expressing ICAM-2. These
transfectants were tested for ICAM-2 expressionby specific binding
to LFA-1. The protocol for fusion and subsequent maintenance of
hybridomas is as previously described (26). Differential reactivity
to ICAM-2 transfected COS cells and untransfected cells was used
initially to screen for ICAM-2 mAbs. Initial screening was per-
formed by ELISA, followed by flow cytometric analysis of putative
ICAM-2 reactive hybridoma supernatants. Positive mAbs were then
screened for reactivity to cell lines known to be either positive
(SKW3) or negative (HeLa) for ICAM-2 by Northern blotting anal-
ysis (17). MAbs selected for further analysis were cloned twice by
limiting dilution and isotyped by ELISA using affinity purified an-
tibodies to mouse immunoglobulins (Zymed Immunochemicals,
San Francisco, CA).
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￿
Fresh tissueswere received at the
Department of Surgical Pathologyat Thomas JeffersonUniversity
and snap-frozen in liquid nitrogen. The tissues were stored at
-70°Cuntiluse. Immunohistological staining was carriedoutfol-
lowing the alkaline phosphatase (AP) anti-alkaline phosphatase pro-
cedure (27). Briefly, 7jLmfrozen tissue sections were air-driedover-
night and fixed in acetone for 10 min. ICAM-1 (RR1/1) and
ICAM-2 (CBRIC2/1) mAb were applied at 1/12,000 and 1/2,000
dilutionsof ascites fluid, respectively, for 30 min followed by brief
washingin Tris-buffered saline, pH 7.6. As anegative control, mouse
serum at a 1/5,000 dilution was applied. After washing, the sec-
tions were incubated with a 1/40 dilution of rabbit anti-mouse
Ig mAb (Dakopatts, Carpinteria, CA) for 30 min. Finally, after
intermittent washing, the cells were incubated with APAAP-
complex (anti-AP mouse mAb preincubated with AP). The last
two steps were repeated in order to enhancethesensitivity of this
procedure. Bound alkaline phosphatase was visualized using new
fuchsin (Sigma Chemical Co.) as substrate. Levamisole wasapplied
in order to block endogenous alkaline phosphatase activity and
Meyer's acid hematoxylin (Sigma Chemical Co.) wasused as coun-
terstain.
Flow Cytometric Analysis.
￿
Adherent cells were removed with
10 mM HBSS/EDTA, washed with PBS/2% FBS and 50 Al of
a 0.5-1.0 x 106 cells/ml suspension was added to either 50 ul of
mAb supernatant or 50 P1 of a 1/200 dilution of mAbcontaining
ascites fluid. After45 minincubation at 4°C, thecellswere washed
andincubated with 100P1 of a 1/20 dilution of FITC-labeled goat
anti-mouse Ig (Zymed Immunochemicals) for45 min at 4°C. The
cells were rewashed andfixedin 1% paraformaldehyde/PBS. Samples
were analyzed usingan EpicsV (Coulter Diagnostics, Hialeah, FL)
flow cytometer. As both primary and secondary mAb were used
at saturating concentrations, membrane antigen expression could
be quantitated as a measure of mean fluorescence intensity using
EPICS Immuno-Brite fluorescent beads (Coulter Diagnostics) to
calibrate the cytometer, and X63 control antibody staining used
to subtract nonspecific fluorescence.
Surface Iodination.
￿
Surface labeling of cells with 1a'I was per-
formed as described using Iodogen (Pierce Chemical Co., Rock-
ford, IL) (28) . Cells were labeled with 1251 (1.0 mCi Na 1251; Amer-
sham Corp., Arlington Heights, IL) and lysed for 45 min at 4°C
in 1 ml of lysis buffer (10 mM Tris HCl pH 8.0, 150 mM NaCl,
1% Triton-X-100, 1% hemoglobin, 1 mM iodoacetamide, 1 mM
PMSF,0.24TIU/ml aprotonin, 0.025% azide). Nuclei andinsoluble
debris were removed by centrifugation at 14,000 g for 20 min and
lysates precleared overnight at 4'C with 100 Al of packed bovine
IgG coupled-Sepharose. The lysate was then incubatedwith 30 P1
packed mAb bound to Sepharose for 2 h. Thebeads were washed
four timesin 25 mM Tris HClpH 8.0,150 mM NaCl,0.1% Triton-
X-100, twice in 25 mM Tris pH 8.0, 150 mM NaCl, and once
in 50 mM Tris pH 8.0. The beads were then treatedwith an equal
volume of 2 x SDS-PAGE sample buffer, boiled for 2 min and
analyzed on 8% vertical slab polyacrylamide gels as previously de-
scribed (29). Proteins were visualized by autoradiography. Treat-
ment of samples with N-glycanase (Genzyme Corp.) was as previ-
ously described (33), using a concentration (3 U/ml) determined
to give optimal cleavage of all N-linked oligosaccharides from the
peptide backbone.
Purification ofLFA-1.
￿
LFA1 was purified from JY lysates on
TS2/4-Sepharose as described previously (30). The LFA-1 bound
to TS2/4-Sepharose waseluted with 50 mM triethylaminepH 11.5,
150 mM NaCl, 2 mM MgCl2, and 1% octyl (3-D-glucopyranoside
(OG). Samples were neutralized and stored frozen at -70°C.
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Adhesion Assay.
￿
Purified LFA1 in 1% OG was diluted 1/10
or 1/20 in 25 mM Tris HCl pH 8.0, 150 mM NaCl, 2 mM
MgCl2 (TSM) and 50 Al absorbed onto 96-well polystyrene micro-
titre plates (LinbroTitertek; Flow Laboratories, McLean, VA) for
2 h at room temperature. Nonspecific binding sites were blocked
for2 h at room temperature with TSM/1% BSA and then washed
twice with PBS/5% FBS/2 mM MgC12/0.5% HSA (assay media).
Specific inhibition of LFA-1 was achieved by an incubation for 30
min at room temperature with a1/200 dilution of TSI/22 ascites.
The number of LFA-1 sites/microtitre well wasdetermined using
saturating amounts of 1211TS1/22 mAb and calculated assuming
monovalent binding of the mAb. Site numbers are expressed per
Um2; the surface area of a microtitre well was determined to be
3.85 x 10' hm2.
Cell lines were harvested, washed once in 10% FBS/RPMI 1640,
resuspended andlabeledwith 15 Wg/mLof2;7'-bis-(2-carboxyethy1)-
5(and-6) carboxyfluorescein (BCECF; Molecular Probes, Inc., Eu-
gene, OR) for 30 min at 37°C. After washing twice in 10%
FBS/RPMI 1640, cells were countedandresuspended in assaymedia.
Adhesion of cell lines to LFA-1-coated plates (31) or endothelial
cell monolayers (15) hasbeen describedpreviously. Briefly, confluent
endothelial cell monolayers in 96-well plates were treated with a
1/200 dilution of the appropriate ascites for 45 min at 37'C and
then unbound mAb was removed by washingbefore thebinding
assay. MAb pretreatment of cells consisted of incubation with a
1/200dilution of ascitesfor 45 min at 4°C, afterwhich 0.75-1.0
x 105 cells were transferred to each well. Cells were allowed to
settle and adhere to either thesolidphaseLFA1 or theendothelial
monolayers for 1 h at 37°C. Washing consisted of 6 aspirations
with either a 21-gauge needle (monolayers) or a 25-gauge needle
(LFA-1-coated plates). Wells were examined microscopically be-
fore and after washing to assess the evenness of cell settling and
damage to the endothelial monolayer. Damage to the monolayer
was neversignificant (<5% area). Fluorescence wasdirectly quan-
titatedfrom the96-well plates using aPandex fluorescence concen-
tration analyzer (Baxter Healthcare Corp., Mundelein, IL).
Adherence of ICAM-2' COS cell transfectants to LFA-1-coated
wells was performed as previously described (31). In short, 5 x
10^ Na251CrOo-labeled transfectants were bound to LFA-1-coated
plates for 1 h at room temperature, and washed with four aspira-
tions through a 26-gauge needle. Boundcells were eluted andquan-
titated by -y counting.
Aggregation Assay.
￿
Aqualitative aggregation assay wascarried
out as described (32). Briefly, 50 pl of a cell suspension (2 x
106/ml) in 10% FBS/RPMI 1640 waspreincubated with a 1/100
dilution of ascites (1/200 final concentration) for 45 min at 4°C.
Thesecells were then stimulated with 50 ng/mL ofPMAandadded
to a flat bottom 96-well microtiter plate (Becton Dickinson, Lin-
coln Park, NJ). Cells were incubated for 2-6 h at 37°C, viewed
with an inverted microscope and aggregation scored visually. Be-
causethese twocelllinesaggregatewith different kinetics, thelength
of theassaywasvaried to maximize PMAinduced aggregation UY:
2 h; SKW3: 5 h). Scores ranged from 0 to 5, where 0 indicates
essentially no cells were clustered; 1 indicates less than 10% ofcells
were in clusters; 2indicatesbetween 10-50% of cells were in ag-
gregates; 3 indicates 50-100% ofcells were in aggregates; 4 indi-
cates nearly 100% of cellswere in largeclusters of aggregates; and
5 indicates that allthecellswere in very compact aggregates. Pho-
tomicrographs of aggregating cells were taken using a Nikon
DiaphotTMD inverted microscope (Nippon Kogaku, Tokyo, Japan)
and phase contrast optics.Results
CONTROL ANTI-ICAM-1 ANTI-ICAM-2
Development ofAnti-ICAM-2 MAbs.
￿
Hybridomas pro-
ducing anti-ICAM-2 mAb were generated by the fusion
ofmyeloma cells with spleen cells from mice immunized with
COS cells transfected with ICAM-2cDNA . TwomAb, CBR-
IC2/1(IgG2a) andCBRIC2/2 (Ig02a) were produced which
bound specifically to COS cells transfected with ICAM-2
cDNA but not to COS cells transfected withICAM-1cDNA
FLUORESCENCE INTENSITY
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Figure 1 .
￿
Flow cytometry analysis of
COS cells transfected with either
ICAM-1 or ICAM-2 cDNA. Trans-
fected COS cells were labeled with ei-
ther nonbinding control mAb X63,
mAb RRI/1 (anti-ICAM-1) or mAb
CBR-IC2/1 (anti-ICAM-2) . CBR-
IC2/2 gave an identical pattern of
staining .
(Fig. 1) or to COS cells transfected with CDM8 vector alone
(data not shown) .
Biochemical Characterization ofICAM-2.
￿
Immunoprecip-
itation of tall labeled ICAM-2+ COS cell lysates showed
that under nonreducing conditions, both anti-ICAM-2 mAb
immunoprecipitated a broad band ofM 54-68,000 from the
ICAM-2 transfectants (Fig . 2 A, lanes 5 and 6) and failed
Figure 2 .
￿
Immunoprecipitation of ICAM-2 . (A) 1251-labeledCOS cell lysates were immunoprecipitated with either nonbinding control mAb X63
ormAb CBRAC2/1 (anti-ICAM-2) ormAb CBR-IC2/2 (anti-ICAM-2) . (B) 1251-labeledCOS cell lysates treated with (+) or without (-) N-glycanase,
and immunoprecipitated with either positive controlmAb W6/32 (anti-HLAA, B, C), nonbinding control mAb X63, mAb CBR-IC2/1 (anti-ICAM-
2) or mAb CBR-IC2/2 (anti-ICAM-2) . MHC Class I contains one Winked carbohydrate and acts as a control for the N-glycanase treatment . (C)
1251-labeled HUVEC lysates immunoprecipitated with mAb CBR-IC2/1 (anti-ICAM-2) and treated with (+) or without (-) N-glycanase, as indi-
cated. All immunoprecipitates were analyzed by8% SDS polyacrylamide nonreducing (A) or reducing (B and C) gels and subjected to autoradiography;
reduced mol wt standards are shown in the far right lane .Table 1.
￿
Distribution of ICAM-1 and ICAM-2 on Normal
Human Tissues"
Tissue
￿
ICAM-1 ICAM-2
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to immunoprecipitate from mock transfectants (Fig. 2 A, lanes
2 and 3). Under reducing conditions, ICAM-2 migrates with
a Mr of 55-65,000 (Fig. 2 B, lanes S and 7). To evaluate
the contribution of glycosylation to this Mr, samples were
treated with N-glycanase, thereby removing all Winked
oligosaccharides (33). Treatment with N-glycanase resulted
in reduction of the ICAM-2 band to an approximate 31,000
ML (Fig. 2 B, lanes 6 and 8), which corresponds closely to
the predicted mature peptide backbone of 28,393 Mr. There-
fore, ICAM-2, like ICAM-1, is a heavily N-glycosylated
protein.
Immunoprecipitation of ICAM-2 from various cell lysates
confirmed the results obtained with the COS cell transfec-
tants. Cultured HUVECrepresent the most abundant source
of ICAM-2 as determined by mRNA expression (17) or by
cell surface expression (Table 2). Immunoprecipitation of
ICAM-2 from HUVEC lysates revealed a species migrating
with an Mr of 55-65,000 under reducing conditions (Fig.
2 C, lane 1). Deglycosylated ICAM-2 from HUVEC (Fig.
2 C, lane 2) was the same Mr as from transfected COS cells.
Unlike ICAM-1, little variation in MI among different cell
types was seen for ICAM-2, as immunoprecipitations from
both SKW3 and JY lysates yielded identical results to those
seen with HUVEC lysates (data not shown).
Tissue Distribution of ICAM-2.
￿
Immunohistochemical
staining offrozen tissue sections revealed ICAM-1 and ICAM-2
to have distinct patterns of distribution (Table 1, Fig. 3).
Normal fetal (21 wk) and adult tissues showed a pattern of
ICAM-1 staining similar to that previously reported (34, 35).
In contrast to ICAM-1, the distribution of ICAM-2 was re-
stricted to the endothelium and some lymphoid cells. ICAM-2
was expressed on all blood vessel endothelium, including high
endothelial venules (Fig. 3 D), and expression was consis-
tently stronger than that seen for ICAM-1. Examination of
germinal centers of lymphoid tissue revealed ICAM-2 to be
absent on most cells (Fig. 3 B and D) . In the spleen, although
ICAM-2 was virtually absent on all lymphocytes in the white
pulp, strong reactivity was seen on the sinus lining cells of
the red pulp (Fig. 3 B). In addition to the marginal reactivity
of follicular mantle cells, ICAM-2 was found to be strongly
expressed on small clusters of lymphocytes within germinal
centers of both spleen and tonsil (Fig. 3 D). As expected,
anti-ICAM-1 mAb showed intense reactivity with the ger-
minal centers oflymphoid follicles, most likely representing
reactivitywith B cells and follicular dendritic cells, while the
follicular mantle and marginal zones of the follicle showed
weaker reactivity (Fig. 3 A and C). ICAM-1 was highly ex-
pressed on tonsil surface and crypt epithelium (Fig. 3 C),
Organs studied: lymph node, tonsil, spleen, thymus, heart, brain,
peripheral nerve tissue, skin, lungs, stomach, small and large intestine,
liver, kidney, ovary, uterus, mammary gland, adrenal gland, and thyroid
gland. Strong expression is denoted as "+" and lack of expression is de-
noted as " - "; "( + )" indicates a partial reactivity. Where not indicated,
tissues were negative for both ICAM-1 and ICAM-2.
t Marginal reactivity for ICAM-2 was observed for follicular mantle cells
in the spleen.
5 Small foci of germinal center lymphocytes were positive for ICAM-2.
All vascular endothelium +
Lymph Node/Tonsil/Spleen
Follicle mantle cells +
Germinal center cells +
Interfollicular/paracortical T cells -
Follicular dendritic cells (FDC) +
Interdigitating cells (IDC) -
Starry sky macrophages +
High endothelial venules
(lymph node, tonsil) +
Tonsil
Oral mucosa +
Crypt epithelia +
Granulocytes
Fibrocytes/fibroblasts
Spleen
Marginal zone cells +
Sinus lining cells +
Thymus
Hassall's corpuscles
Cortical thymocytes
Medullary thymocytes
Skin
Epidermal cells, Langerhans' cells,
Melanocytes, Sweat gland cells
Fibrocytes/fibroblasts
Lungs
Alveolar lining cells, pneumocytes
type I and II, alveolar macrophages +
Capillary endothelial cells +
Liver
Hepatocytes +
Kupffer's cells +
Sinus lining cells +
Bile duct cells -
Kidney
Endothelial cells of the glomerulum +
Cells of Bowman's capsule, basal
membrane of the glomerulum
capillaries, tubular cells -
Intertubular spindle cells +
Small Intestine
Peyer's patches +
Lymphocytes of the mucosal stroma +258
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of ICAM-1 in the medulla and only low levels in the cortex,
whileICAM-2 reactivitywas confined to vessel endothelium.
In the cortical region ICAM-1 expression was primarily focal
on dendritic and epithelialcells, whereas high levels ofICAM-1
in the medulla was localized to both the dendritic/macro-
phage cells and the thymocytes.
In nonlymphoid organs, several differences in expression
were observed between ICAM-1 and ICAM-2 (Table 1). While
macrophages, fibroblast-like cells, and dendritic cells expressed
high levels of ICAM-1 in most tissues studied, ICAM-2 ex-
pression in tissues was restrictedto blood vessel endothelium.
Additional ICAM-2 expression was seen only in the liverand
the kidney. In the liver, ICAM-2 was weakly expressed on
Kupffer cells and some sinusoidal lining cells (Fig. 3 F).
ICAM-1 by comparison was strongly expressed by Kupffer
cells and sinusoidal lining cells (Fig. 3 E). In kidney, the glo-
merular capillary endothelium expressed ICAM-2, as did the
intertubular spindle cells (Fig, 3 M. The ICAM-2 expres-
sion in kidney, although weaker than ICAM-1, was similar
in its distribution (Fig. 3 G). These exceptions aside, ICAM-2
was not present on any othertissues studied, including small
and large intestine, striated and smooth muscle, brain, thy-
roid gland, and skin.
Immunofuorescence Flow Cytometry of ICAM-2 Membrane
Expression. Flow cytometric analysis of human tumor cell
lines and PBLs supported the results obtained in frozen tissue
sections (Table 2). Resting lymphocytes and purified T cells
expressed both ICAM-1 and ICAM-2 at low levels, although
ICAM-2 was always significantly higher in expression than
ICAM-1. The pattern of expression for ICAM-2 differed
from ICAM-1 in that nearly all resting cells were ICAM-2
positive and expression increased only slightly upon PHA
activation. Two-color flow cytometry revealed resting T
(CD3+) and B (CD20+) lymphocytes to express equivalent
amounts of ICAM-2 on their cell surface (data not shown).
In contrast to resting lymphocytes, freshly purified mono-
cytes showed greater ICAM expression, with ICAM-1 and
ICAM-2 being generally equivalent. In vitro culturing of
monocytes has been used as a method of obtaining macro-
phage-like CD16 + cells (24) . Upon culturing of monocytes
to induce macrophage differentiation, ICAM-2 expression re-
mained unchanged, whereas the inducibility of ICAM-1 was
consistent with published data (34).
Expression of ICAM-2 on cell lines was coordinate with
Northern blotting analysis. Lines which had been previously
shown to express ICAM-2 mRNA (HUVEC, SKW3, Jurkat,
BBN, Ramos, U937) or lack ICAM-2 mRNA (HeLa, FS1,2,3)
showed corresponding patterns of cell surface expression (Table
2). All T and B lymphoblastoid lines examined expressed con-
siderable ICAM-2, while other cell lines exhibited a broad
range of expression. Treatment ofseveral cell lines (HUVEC,
JY, and SKW3) with phosphoinositol-phospholipase C (PI-
PLC), revealed no PI-linked form of ICAM-2 as cell surface
expression remained unchanged (data not shown). Mouse lym-
phoblastoid and fibroblastic cell lines did not react with the
anti-human ICAM-2 mAb, implying that these mAb did .
not crossreact to murine ICAM-2.
ICAM-2 Expression on Cultured Endothelial Cells.
￿
Of all
cell types examined, ICAM-2 was most highly expressed on
endothelial cells. We examined the relative levels of ICAM
expression on resting and stimulated human umbilical vein
endothelial cells (Fig. 4). Resting endothelial cells showed
low basal levelexpression of ICAM-1 and approximately 10-
fold higher ICAM-2 expression. The level of ICAM-2 ex-
pression was also significantly higher than that seen for ei-
ther LFA-3 or HLAA, B, C. Upon stimulation ofendothelial
cells with TNF-ce, ICAM-1 expression increased after 4 h,
becoming maximal after 24 h stimulation, while ICAM-2
expression remained unchanged. LFA3 was largely unaffected
by cytokine stimulation, whereas HLAA,B,C showed slightly
increased expression, as previously reported (15, 36, 37). Iden-
tical findings were obtained with a variety of other stimuli
including Ilrl0, LPS, and IFN--y (data not shown) . ICAM-2
therefore was found to be constitutively expressed at high
levels on HUVEC and, unlike ICAM-1, was not increased
by stimulation with inflammatory mediators.
Functional Characterization ofICAM-2 MAh
￿
To determine
whether CBR-IC2/1 and CBR/IC2/2 couldinhibit ICAM-
2-LFA-1 interaction, binding of ICAM-2+ COS cells to
purified LFA-1 was performed in the presence ofthese mAb
(Fig. 5) . A high percentage of transfected cells bound to
purified LFA-1 in the presence of control mAb W6/32, and
this was totally inhibitable by an anti-LFA-1 mAb. Of the
Figure 3.
￿
Photomicrograph ofimmunohistochemical alkaline phosphatase anti-alkalinephosphatase (APAAP) staining offrozen tissues withanti-ICAM-1
(RR1/1) and anti-ICAM-2 (CBR-IC2/1) mAb (magnification x 200). (A) Staining of spleen with anti-ICAM-1 mAb. Note that the germinal center
(GC) cells, follicular mantle (FM) cells and marginal zone (MZ) cells are positive for ICAM-1. Endothelium of small vessels is also positive (arrow).
(B) Staining of spleen with anti-ICAM-2 mAb. With the exception of very faint staining of the follicular mantle (FM) lymphocytes, no staining of
the white pulp is observed including germinal center (GC) and marginal zone (MZ) cells. The red pulp (RP) shows intense staining of the sinus lining
cells. Small vessel endothelium is stained (arrows). (C) Normal tonsil stained with anti-ICAM-1 mAb. The germinal center (GC) cells show strong
reactivity, whereas the follicular mantle (FM) cells are only weakly reactive. Virtually all vascular endothelium, including high endothelial venules,
are positive (arrows). ICAM-1 is also present on the surface and crypt epithelium (E) of tonsil. (D) Normal tonsil stained with anti-ICAM-2 mAb.
Note that virtually all vascular endothelium is positive, including high endothelial venules (HEV). Small clusters ofgerminal center (GC) lymphocytes
are also positive for ICAM-2 (arrow). The follicular mantle (FM) cells show negative to faint reactivity. Epithelium is negative (not shown). (E) Normal
liver stained with anti-ICAM-1 mAb. Kupffer cells and sinusoidal endothelium are stained (arrows). The endothelium of the vessels (VS) in the portal
fields are also positive. Liver epithelium and bile ducts (BD) are negative. (F) Normal liver stained with anti-ICAM-2 mAb. Sinuoidal endothelium
is largely negative for ICAM-2 and only weak reactivity is found for Kupffer cells (arrow). Positive staining is found for the endothelium of the vessels
(VS) in the portal fields. Liver epithelium and bile duct (BD) epithelium are negative. (G) Normal kidney stained with anti-ICAM-1 mAb. Note
that the endothelium of all glomerular capillaries is positive. Some reactivity is also observed with the intertubular spindle cells. (M Normal kidney
stained with anti-ICAM-2 mAb. Note the pronounced staining of all glomerular capillaries. Reactivity to intertubular spindle cells is also seen.
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Relative Surface Antigen Expression of ICAMs by
￿
two anti-ICAM-2 mAb, CBR-IC2/1 caused slight inhibi-
Immunofluorescence Flow Cytometry
￿
tion, whereas CBR-IC2/2 completelyblocked adherence to
levels seen in the presence of anti-LFA1 mAb. A combina-
tion of both anti-ICAM-2 mAb gave no additional inhibi-
tion to that seen when usingCBRIC2/2 alone. Both mAb
were used at saturating concentrations, and this inhibitory
effect could be diluted out. Similar results were obtained using
mouse L cells stably expressing human ICAM-2, demon-
strating the ability of mAb CBRIC2/2 to completely in-
hibit ICAM-2 interaction was purified LFA1(data not shown).
CBR-IC2/1 and CBRAC2/2 were determined to recognize
nearby but distinct epitopes on ICAM-2, because although
CBRIC2/2 would completely block CBR-IC2/1 binding,
the latter could only partially block the former (data not
shown) .
Effect ofAnti-ICAM-2 MAbs on Homotypic Aggregation.
We examined the ability of anti-ICAM-1 and anti-ICAM-2
mAb to inhibit LFA1-dependent homotypic aggregation of
several cell lines(Table 3 and Fig. 6). PMAinduced aggrega-
tion ofJY, an EBVtransformed B lymphoblastoid cell line,
was previously found to be inhibitable almost completely by
the blocking anti-ICAM-1 mAb, RR1/1 (10). Alone, anti-
ICAM-1 mAb was found to inhibit most aggregation (Fig.
6 C), but when used in conjunction with anti-ICAM-2 mAb
aggregation was inhibited completely(Fig. 6 E); to the same
extent as with anti-LFA-1 mAb (Fig. 6 F). Consistent with
the functional characterization of both CBRIC2/1 and
CBR-IC2/2, when the anti-ICAM-2 mAb were used sep-
arately with RR1/1, only CBRIC2/2 inhibited aggregation.
Aggregation was not inhibited by the anti-ICAM-2 mAb
alone (Fig. 6 D); this is due to the presence of ICAM-1 and
the overriding role it plays in LFA1-dependent aggregate for-
mation of this cell line. PMA treatment of cells resulted in
little change in surface expression ofeither ICAM-1, ICAM-2,
or LFA-1 during the course of the assay (data not shown).
After 12-24 h however, ICAM-1 expression increased and
ICAM-2 showed a slight decrease.
PMAinduced aggregation ofSKW3 was shown to be LFA
1-dependent, but ICAM-1-independent (Table 3). This is
consistent with previously published reports (10). Anti-
ICAM-2 mAb had no effect on SKW3 aggregation either
alone or in combination with RR1/1 (Table 3). Given the
ability of RR1/1 and CBR-IC2/2 to inhibit ICAM-1 and
ICAM-2-dependent binding by other cells, these results sug-
gest the presence of a-third ligand for LFA1 on SKW3.
Efect ofAnti-ICAM-2 MAbs on Cell Line Binding to LFA-1.
To better define this putative third LFA1 ligand, binding of
Membrane expression determinedby immunofluorescence flow cytom-
etry with RRl/1 for ICAM-1, CBR-IC2/1 for ICAM-2, and W6/32
for HLA-A,B,C. Values are determinative of at least two experiments.
Fluorescent beads were used to calibrate the cytometer such that one unit
was approximately 103 fluorescein equivalents (Counter Diagnostics).
t Miscellaneous cell lines include: Human umbilical vein endothelial cells,
HUVEC; human breast carcinoma, ZR-75-1; human hepatocellular car-
cinoma, Hep G2; human epitheloid carcinoma cell line, HeLa; human
rhabdomyosarcoma, RD 3/5; humanfibrosarcoma, FS 1,2,3; humanglio-
blastoma, A-172; and the Reed-Sternberg line, L428.
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Cell line/type
Specific
ICAM-1
linear fluorescence
intensity'
ICAM-2 HLA
Lymphocytes 13 45 840
T lymphocytes 14 40 920
1 day PHA-blasts 64 40 1,100
4 day PHA-blasts 200 55 1,600
7 day PHA-blasts 70 32 1,100
Monocytes 72 87 990
Cultured monocytes 293 80 1,200
Neutrophils 5 0 275
NK cells 12 32 1,050
Erythrocytes 0 0 0
T lymphoblastoid
SKW3 0 114 670
Jurkat 21 181 200
Sup T 57 178 180
Molt 4 28 240 253
B lymphoblastoid
JY 125 130 1,600
Ramos 190 260 670
Raji 282 72 468
Daudi 260 135 260
ER-LCL 150 110 705
BBN 100 60 215
RPMI 8866 146 117 618
Monocytic
U937 31 29 220
HL60 0 23 268
Melanomas
BK 181 8 265
RPMI 7591 194 0 710
Erythroleukemic
K562 155 95 6
HEL 58 118 950
Miscellaneoust
HUVEC 41 470 260
ZR-75-1 105 30 105
Hep G2 142 17 140
HeLa 225 0 155
RD3/5 0 11 208
FS1,2,3 225 0 645
A-172 0 0 385
L428 835 169 16s
0 m
d
N
0
MHC CLASS I
￿
LFA-3
￿
CAM-l-
￿
ICAM-2
t to tm
Table 3.
￿
Inhibition of PMA-induced Aggregation with LFA-1, ICAM-1 and ICAM-2 rnAb"
Cell type
￿
Control
￿
«LFA-1
￿
«ICAM-1
￿
«ICAM-2
JY
￿
4
￿
0
￿
1
￿
4
SKW3
￿
4
￿
0
￿
4
￿
4
" FreshJY or SKW3 cells were preincubated at 4°C for 45 min with either no mAb (control) or 1/200 dilution of mAb containing ascites: TS1/22
(anti-LFA-la), RRl/1 (anti-ICAM-1), CBR-IC2/1+CBR-IC2/2 (anti-ICAM-2), RR1/1+CBR-IC2/1+CBR-IC2/2 (anti-ICAM-1+2), or W6/32
(anti-HLA-A,B,C). Cells were then stimulated with 50 ng/ml of PMA, and aggregation scored visually after either 2 h (TY) or 5 h (SKW3).
t Aggregation scored as described in Materials and Methods. Scores: 0, no cells clustered; 1, <10% of cells aggregating; 2, 10-50% of cells ag-
gregating; 3, 50-100% of cells aggregating; 4, nearly 100% of cells in loose aggregates; 5, 100% of cells in very compact aggregates.
FLUORESCENCE INTENSITY
Figure 5.
￿
Effect of ICAM-2 mAb on binding of ICAM-2-expressing
COS cell transfectants to purified LFA-1. Binding of s1Cr-labeled ICAM-2*
COScell transfectants was measured by incubating cells on LFA-1-coated
microtiter wells for 60 min at room temperature and then washing four
timesby aspiration. Site densityofLFA-1as determined byradioimmuno-
assaywas 1,100 sites/P,,,2 .Cells were incubated with saturating concen-
trations of control mAb W6/32 (anti-HLA-A,B,C); mAb CBRIC2/1
(anti-ICAM-2); mAbCBRIC2/2 (anti-ICAM-2); or mAbCBR-IC2/1
andmAbCBRIC2/2(anti-ICAM-2). Alternatively, theabsorbed purified
LFA-1 was pretreated with mAbTSl/22 (anti-LFA-la). Onerepresenta-
tive experiment of five is shown and error bars indicate one standard
deviation.
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UNSi1MULATED
4 HOURS
24 HOURS
Figure 4.
￿
Immunofluorescence flow
cytometryanalysis of HUVECbefore
andafter TNF-a stimulation.HUVEC
werestimulatedfortheindicatedlength
of time with 20 ng/mL TNF-a and
then labeledwith either mAb W6/32
(anti-HLA-A,AC), mAbTS2/9(anti-
LFA-3), mAbRRl/1 (anti-ICAM-1),
mAb CBI-IC2/1 (anti-ICAM-2), or
nonbinding control mAb X63 (thin
lines), and then followed by FITC
anti-mouse Ig.
«ICAM-1+2
￿
«HLA
cell lines to purified LFA-1 was performed (Fig. 7). Consis-
tent binding of all cell lines to purified LFA1 was observed
in the presence of control X63 mAb. Similar binding was
achieved if no mAbwas addedor ifothercontrolmAbs were
used (W6/32, TS2/9, TS2/16; data not shown). Paralleling
the aggregation results, JY binding to purified LFA1 was
largelyinhibitable with anti-ICAM-1 mAb alone, and when
combined with anti-ICAM-2mAb, binding wasfurther in-
hibitableto thelevel seen in thepresence ofanti-LFA1mAb.
Little inhibition wasseen when anti-ICAM-2mAbwere used
alone. SKW3 binding to LFA1 was only slightly inhibited
with acombinationofmAbto ICAM-1 andICAM-2,whereas
bindingwas abolished with LFA-1 mAb. This third mecha-
nism of adhesion to LFA1 was also present at suboptimal
LFA1 sites densities and was resistant to stringent washing
conditions (21-gauge needle aspiration) (data not shown).
Numerous other cell lines were tested and several Ourkat,
Sup T, Ramos, Molt 4) also expressed an ICAM-1, ICAM-2-
independent pathway of adhesion to LFA1(data not shown).
Bindingof unstimulated HUVEC to purified LFA1 was found
to be entirely ICAM-1 and ICAM-2-dependent. MAb to ei-
ther ICAM-1 or ICAM-2 hadlittle effect alone, whereas the
combination of mAb to ICAM-1 and ICAM-2 eliminated
binding as effectively as LFA1 mAb.
B Lymphoblastoid Cell Adhesion to HUVEC.
￿
The adhe-
sion of theJY B lymphoblastoid cell line to HUVEC is an
ideal in vitro system in which to study LFA1-dependent
binding of lymphocytes to endothelial cells (Fig. 8). Several
mechanisms of lymphocyte-endothelial adhesion exist, ofFigure 6 .
￿
JY aggregation is completely inhibited by mAb to ICAM-1 and ICAM-2 . Photomicrographs ofJY cells aggregating in the presence of
PMA, with : (A) control mAb X63; (B) anti-HLA framework mAb (W6/32); (C) anti-ICAM-1 mAb (RR1/1) ; (D) anti-ICAM-2mAb (CBR-IC2/1
and CBR-IC2/2) ; (E) both anti-ICAM-1 and anti-ICAM-2 mAb; (F) anti-LFA-la chain mAb (TS1/22) .
which LFA-1-ICAM and VLA4VCAM-1 are the most im-
portant and intensively studied (1, 38, 39) . SinceJY cells lack
01 expression (A . de Fougerolles and T.A . Springer, unpub-
lished observations), adhesion of these cells to endothelium
allows the LFA-1-ICAM interactions to be studied indepen-
dently (15) of any /31-dependent interactions, such as VLA-
4VCAM-1 . The contribution of CD2-LFA-3 interactions
to initial lymphocyte-endothelial cell adhesion has previously
been shown to be minimal (15), and this is reflected in the
inability of LFA-3 mAb to inhibit JY binding to HUVEC
(Fig . 8) . Previously, it was shown that binding ofJY cells
to HUVEC occurred via two LFA-1-dependent pathways,
an inducible ICAM-1-dependent pathway and an uninducible
ICAM-1-independent pathway (15) . To examine ifthisICAM-
1-independent pathway of adhesion was due to ICAM-2, JY
adhesion toHUVEC was assayed in the presence ofICAM-2
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￿
Adhesion of cell lines to purified LFA-1 reveals the presence
of a novel LFA-1 ligand. Binding of BCECF4abeled cell lines was mea-
sured by incubating cells on LFA-1-coated microtiter wells for 60 min
at 37°C and then washing six times by aspiration. Site density of LFA-1
as determined by radioimmunoassay was 1100 sites/p,mz . Cells were in-
cubated in the presence ofcontrolmAb X63 ; MabRR 1/1 (anti-ICAM-
1) ; mAbCBRIC2/1 andmAb CBR-IC2/2 (anti-ICAM-2) ; mAb RRIA,
mAb CBR-IC2/1 and mAb CBR-IC2/2 (anti-ICAM-1+2), or mAb
TSI/22 (anti-LFA-la) . One ofeight representative experiments is shown
and error bars indicate one SD.
mAb (Fig. 8) . ICAM-2 mAb inhibited binding ofJY cells
to unstimulated endothelium more strongly than ICAM-1
mAb . Treatment ofHUVEC with TNF-a for 24 h, resulted
in a significant increase in JY adhesion (Fig. 8) . This adhe-
sion was inhibited morebyICAM-1 mAb thanICAM-2 mAb,
and the combination of ICAM mAb inhibited similarly to
LFA1 mAb . The ICAM-1 component of adhesion was in-
ducible, whereas the amount of binding seen in the presence
of ICAM-1 mAb, in other words the ICAM-2 component,
was constant . Studies with 24 h LPS stimulated HUVEC
and 4 h TNF-cx stimulated HUVEC yielded similar results,
however, less ICAM-1-dependent binding was seen with en-
dothelium stimulated for 4 h than 24 h (data not shown)
as expected from flow cytometry data on the induction of
ICAM-1 . These results demonstrate that ICAM-2 is the pre-
dominant LFA1 ligand on resting endothelial cells whereas
ICAM-1 is the predominant ligand on stimulated endothelial
cells .
Discussion
ICAM-2 was initially described and characterized as acDNA
clone that encoded a counter receptor for LFA-1 (17) . In this
study we have reported the production of two murinemAb
to ICAM-2 which allow the characterization oftheICAM-2
molecule. ICAM-2 was found to be a broad band by SDS-
PAGE o£Mr 55-65,000 under reducing conditions. Unlike
ICAM-1 (34), little variation in size was seen for ICAM-2
immunoprecipitated from different cell lines . Based oncDNA
sequence, ICAM-2 has a polypeptide backbone ofM r 28,393
and six potential Winked glycosylation sites (17) . Glycosy-
lation of ICAM-2 accounted for an increase in M, of
30,000-35,000, about 5,000 M r/N-linked site. Compara-
tively, ICAM-1 has 8 Winked glycosylation sites, which
account for about 41,000 M r of the apparent Mr in SDS-
PAGE . An increase of about 3,000 Mr/N-linked glycosyla-
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Figure 8 .
￿
JY binding to HUVEC is solely ICAM-1 and ICAM-2-de-
pendent . Confluent monolayers ofHUVEC in 96-well plates were either
untreated or stimulated for 24 h before assay with 20 ng/ml recombinant
TNF-a. BCECF-labeled JY cells were bound to the endothelial cell
monolayer for 60 min at 37°C and then washed by aspiration six times .
Before binding, JY cells were incubated with saturating concentrations
ofcontrolmAb X63; mAb'17S2/9 (anti-LFA3) ; mAb RRI/1 (anti-ICAM-
1) ; mAb . CBR-IC2/1 and mAb CBR-IC2/2 (anti-ICAM-2); or mAb
RR1/1,mAbCBRIC2/1 andmAbCBRIC2/2 (anti-ICAM-1+2). Al-
ternatively, HUVEC were pretreated with mAb TSI/22 (anti-LEA-la) .
One representative experiment of four is shown and error bars indicate
one SD.
tion site is more typical of glycoproteins ; therefore, the
Winked carbohydrates ofICAM-1 and ICAM-2 appear un-
usually large . There are six and threeWinked glycosylation
sites in domains 1 and 2 of ICAM-2 and ICAM-1, respec-
tively. The ligand binding region ofICAM-1 has been local-
ized to domain 1 (14) ; the comparable region in ICAM-2
is more heavily glycosylated.
The overall tissue distribution ofICAM-2 is more restricted
than that of ICAM-1 . ICAM-2 is restricted largely to en-
dothelium and certain interstitial cells . Aside from vascular
staining, ICAM-2 is not found at all in the thymus, while
discrete clusters of ICAM-2 positive cells are seen in lym-
phoid tissue germinal centers. As it is difficult to distinguish
between the tightly clustered follicular dendritic cells(FDC)
and the surrounding germinal center B cells, this discrete
staining pattern could reflect reactivity to either FDCs or
B cells or a subpopulation thereof. Previous reports have
demonstrated that FDCs display a unique antigenic pheno-
type, including expression ofmany adhesion molecules such
as ICAM-1 (40) . The expression ofICAM-2 on these cells
may contribute in antigen presentation by interacting with
LFA-1 on circulating lymphocytes . The distribution of
ICAM-1 is consistent with previous reports (34, 35) and
parallels closely that ofHLADR . ICAM-1 is present on non-
lymphoid cells, including vascular endothelium, thymic and
mucosal epithelial cells, as well as B cells and follicular den-
dritic cells in the germinal centers of lymphoid follicles.
The distributions of ICAM-1 and ICAM-2 on cell lines
parallel closely the immunohistology results . Expression of
ICAM-2 was most pronounced on HUVECs, where its level
on resting endothelial cells was consistently 10-15-fold higher
than that for ICAM-1. ICAM-2 expression on resting lym-phocytes was several-fold higher than that seen with ICAM-1,
while monocytes expressed equivalent levels of ICAM-1 and
ICAM-2. ICAM-1 is strongly expressed on melanoma and
carcinoma cells (41, 42), whereas ICAM-2 is not. The weak
expression of ICAM-2 observed on leukocytes by immuno-
fluorescence flow cytometry was undetectable by immuno-
histochemical analysis of tissue sections, presumably due to
the lower sensitivity of this technique.
The inducibility of ICAM-1 and constitutive expression
of ICAM-2 have important implications for their role in
inflammatory and immune responses. Previous studies have
shown that although ICAM-1 was expressed at very low basal
levels on endothelial cells, it was readily inducible by exposure
of HUVEC to recombinant IMot, IIrl,3, IFN-.y, TNF-a,
and LPS (15, 36, 37). A second noninducible ligand on en-
dothelial cells for LFA-1 was described (15) and was postu-
lated to be ICAM-2 (17) . Indeed, our studies on ICAM-2
confirmed these predictions. ICAM-2 surface expression on
endothelial cells is unaffected by a variety of inflammatory
cytokines. Similarly, while ICAM-1 was upregulated upon
stimulation ofresting lymphocytes, ICAM-2 expression was
unchanged. These results point towards ICAM-1 being the
major ligand for LFA-1 during inflammatory or immune re-
sponses, while ICAM-2 is of more relative importance in the
unstimulated resting state or early on during a response be-
fore ICAM-1 expression is increased.
ICAM-2 is the predominant LFA1 ligand on resting en-
dothelium, and therefore this pathway of adhesion between
lymphocytes and resting endothelium may have important
consequences for normal recirculation of lymphocytes through
tissue endothelium. The importance of LFA-1 in recircula-
tion is demonstrated by the 40 to 60% reduction in normal
lymphocyte migration into lymph nodes and Peyer's patches
that is seen following in vivo treatment with LFA1 mAb
(43) . Naive and memory T cells show distinct pathways of
recirculation, as memory T cells selectively exit from blood
through peripheral tissue endothelium, whereas naive T cells
exit through lymph node high endothelial venules (44).
ICAM-2 is an attractivecandidate ligand to facilitate memory
T cell recirculation as it is basally expressed at high levels
on resting endothelium and memory T cells have increased
LFA-1 expression (45). Similarly, resting T lymphocytes ex-
press little or no ICAM-1, and as such ICAM-2 may be im-
portant in initial T cell adhesion with antigen presenting cells
that bear LFA-1 (46, 47). Indeed, in both allogeneic and au-
tologous mixed lymphocyte reaction a role is suggested for
LFA-1 ligand(s) other than ICAM-1 (48). Another immune
reaction where cell-to-cell contact is required is direct cyto-
toxicity. Lysis of certain targets by T cells appear to occur
in an ICAM-1-independent, LFA-1-dependent manner (16).
It will be of interest to see what role ICAM-2 plays in these
phenomena.
A mAb that blocks binding ofICAM-2 to LFA-1 was used
to investigate several phenomena that were known to be
LFA1-dependent, yet ICAM-1-independent (10, 15). One
such case involves homotypic aggregation of JY, an EBV
transformed B lymphoblastoid cell line. PMA-induced aggre-
gation of this cell line, while completely LFA-1-dependent,
was only partially inhibitable with mAb to ICAM-1 (10).
Our results confirm these findings and extend them to show
that ICAM-2 accounts for the remaining aggregates. While
the ICAM-2 mAb in combination with ICAM-1 mAb can
inhibit all aggregation, the ICAM-2 mAb alone has no in-
hibitory effect on aggregation. This observation highlights
one important difference between ICAM-1 and ICAM-2,
namely their relative avidity for LFA1. By immunofluores-
cence ICAM-1 and ICAM-2 are expressed at similar levels
on JY, yet by far the major adhesive component in homo-
typic aggregation and binding to purified LFA-1 is due to
ICAM-1. Similar findings are seen with HUVEC binding
to LFA1 andJY adhesion to HUVEC, where although resting
endothelial cellsexpress 10-fold more ICAM-2 than ICAM-1,
the effect of the anti-ICAM-2 mAb is roughly equivalent
to that seen with the anti-ICAM-1 mAb. Even after 4 h
TNF-a stimulation of endothelial cells, when ICAM-2 sur-
face expression is still several-fold greater than ICAM-1, JY
binding to HUVEC is largely inhibitable by ICAM-1 mAb
(datanot shown). Lastly, when comparing adhesion to purified
LFA-1 of transfected COS cells expressing equivalent levels
of ICAM-1 and ICAM-2, the ICAM-1 expressing cells were
more resistant to increased washing shear force than were
the ICAM-2 expressing COS cells (17) . All of these experi-
ments point towards ICAM-2 being the lower affinity ligand
for LFA-1. At the present time the exact reason for the lower
affinity of LFA1 for ICAM-2, as compared to ICAM-1, is
not known, although differences in LFA-1 binding sites, and
decreased accessibility ofLFA1 for ICAM-2, due to its shorter
two domain structure and increased level of glycosylation,
are all plausible explanations.
Another important distinction between ICAM-1 and
ICAM-2 is the spectrum of integrins with which they in-
teract. Although ICAM-1 has been shown to interact with
another leukocyte integrin, Mac-1 (49), ICAM-2 shows no
detectable binding to Mac-1. Presently, LFA-1 is the only
known counter-receptor for ICAM-2.
Aside from purely adhesive interactions, there may well
be qualitative differences in how ICAM-1 and ICAM-2 in-
teract with LFA-1. Previously, it had been shown that resting
T cells could be actived through combination of immobi-
lized anti-CD3 antibodies and purified ICAM-1 (50, 51). It
will thus be interesting to see if ICAM-2 can exert similar
effects, and ascertain if signal transduction via LFA-1 is the
same when using ICAM-2 as ligand. Similarly, activation of
T cells through CD3 causes a change in LFA-1 avidity from
low to high, resulting in increasedbinding ofT cells to purified
ICAM-1 (30). By examining if this avidity change also ex-
tends to ICAM-2 binding, it would be possible to further
dissect differences between the ICAMs. Another area where
ICAM-1 and ICAM-2 could potentially differ is in their as-
sociation with cytoplasmic proteins. Preferential interaction
with either ICAM-1 or ICAM-2, perhaps dictated in focal
adhesions by the contact distance between cells, could then
result in different cytoskeletal changes affecting the overall
structure and organization of the cell.
Certain LFA-1-dependent ICAM-1-independent phenom-
ena were found not to be accountable for by ICAM-2, thus
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third ligand was found to be largely responsible for SKW3
PMA-inducedhomotypic aggregation, and several cell lines,
including SKW3, were found to bind to LFA1-coatedplastic
in an ICAM-1, ICAM-2-independent manner. Thestrength
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Note added in proof: Nortamo et al. (52) recently reported a more limited characterization of ICAM-2
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tamo et al. (52) find the reverse. In further contrast, Nortamo et al. (52) report that only 39% ofunstimu-
latedumbilicalvein endothelial cells are positive for ICAM-2 and that ICAM-2 is expressedmore weakly
than ICAM-1.
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